Hormonal, Metabolic, and Signaling Interactions in PAH

Part of paid clinical trials in Nashville, Tennessee.

Sponsor
Vanderbilt University Medical Center
Study ID
NCT01884051
Status
Recruiting
Apply to this trial

Conditions

  • Appetite Suppressant Associate PAH
  • Heritable Pulmonary Arterial Hypertension
  • Idiopathic Pulmonary Arterial Hypertension
  • Scleroderma Associated Pulmonary Arterial Hypertension

Eligibility Criteria

Sex
ALL
Age
N/A - 90 Years
Healthy Volunteers
Accepted

Study Details

Our hypothesis is that optimal treatment of the dysfunctional metabolic pathways which underlie PAH will improve pulmonary vascular function and consequences of the disease.

Key Dates

Start date
Sep 30, 2012
Status verified
Sep 2025
Primary completion
Jul 31, 2032
Completion
Jul 31, 2032

Study Design

Enrollment
1,899 participants (estimated)

Arms

  • Arm: PAH patients
    Patients diagnosed with WHO Group 1 PAH
  • Arm: Healthy subjects
    Subjects who have been evaluated for heart and lung disease and found to be healthy

Primary Outcome Measure

Ratio of sex hormone metabolites [ Time Frame: 5 years ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
Vanderbilt University Medical CenterNashvilleTennessee37232-

Find similar trials in Nashville, TN

By research site
Vanderbilt University Medical Center· Nashville, TN

Related Studies